工业微生物代谢途径调控的基因敲除策略

基因敲除技术是一项重要的分子生物学技术,在工业微生物代谢工程中具有广泛应用。以下从基因敲除技术的遗传重组原理出发,总结了基因敲除策略的类型、特征和应用,重点介绍了采用线性双链DNA的λRed同源重组系统、使用环状质粒载体介导的单交换或双交换同源重组策略以及采用转座酶介导的转座重组等几种主要的基因敲除方法,进一步展望了基因敲除技术的发展前沿和应用前景。     

基于pDS132的基因敲除中创伤弧菌氯霉素的耐药性变化及影响

【背景】基于自杀载体的基因敲除在单基因敲除上的应用较为常见,但在多基因敲除过程中细菌耐药性的变化及对后续敲除的影响尚未明确。【目的】探究基于自杀载体pDS132的创伤弧菌vvhA与rtxA1双基因敲除株构建过程中,创伤弧菌对氯霉素耐药性的变化及对后续基因敲除的影响。【方法】基于自杀载体pDS132的同源重组法构建创伤弧菌YJ016的单基因敲除株YJ016-ΔvvhA、YJ016-ΔrtxA1和双基因敲除株YJ016-ΔvvhAΔrtxA1,记录单交换筛选时的氯霉素浓度与筛选平板上成功重组的菌株所占比例。琼脂稀释法测定野生型与敲除株的氯霉素最低抑菌浓度(Minimum InhibitoryConcentration,MIC)和抗性突变频率,纸片扩散法测定菌株对其他药物的敏感性,分析其对单交换筛选的影响。【结果】单基因敲除株的氯霉素MIC及氯霉素抗性突变频率高于野生型;双基因敲除株的庆大霉素抑菌圈直径小于野生型。单基因敲除时,单交换重组菌株的占比为100%(20/20);在YJ016-ΔvvhA上敲除rtxA1基因,氯霉素筛选浓度为2、4μg/mL时,单交换重组菌株的占比分别为40%(8/20)、5%(1/20);在YJ016-ΔrtxA1上敲除vvhA基因,氯霉素筛选浓度为2、4μg/mL时,单交换重组菌株的占比均为0%(0/20)。【结论】基于自杀载体pDS132的基因敲除中创伤弧菌氯霉素的耐药性升高,可能影响后续单交换重组的筛选,该结果为基于自杀载体的同源重组技术应用于多基因敲除提供了参考。     

一种基于单交换原理的地衣芽孢杆菌基因敲除方法及应用

目的：基于同源单交换原理构建地衣芽孢杆菌基因快速敲除方法,提高基因敲除效率。方法：以地衣芽孢杆菌（Bacillus licheniformis）20085内切纤维素酶基因celb为拟敲除对象,利用重叠PCR技术将celb基因内约500bp片段与氯霉素抗性基因（Cm^r）相连接,经末端单酶切后电转化至B.licheniformis 20085感受态细胞中,仅通过一次同源单交换,将抗性基因Cm^r插入至celb基因内部,实现目的基因的敲除。结果：经过氯霉素抗性筛选和基因组PCR鉴定,成功获得celb基因缺失菌株B.licheniformis 20085Δcelb;发酵验证结果显示,B.licheniformis 20085Δcelb较原始菌株滤纸崩解能力显著降低,其中发酵60h后内切纤维素酶（CMC酶）活力由1.86U/ml降低至0.50U/ml,表明celb基因在地衣芽孢杆菌降解纤维素的过程中起着重要作用。结论：通过重叠PCR技术结合同源单交换原理能够实现地衣芽孢杆菌目的基因的快速敲除,为该菌株甚至其它微生物提供了一种基因功能快速鉴定的手段。     

利用Red系统快速敲除家蚕核型多角体病毒orf60基因

用Red重组系统和最近构建的家蚕核型多角体病毒(BmNPV)bacmid在大肠杆菌BW25113中快速地敲除BmNPVorf60基因。从大肠杆菌BmDH10Bac中提取BmNPVbacmid,将其电转化到含有质粒pKD46(能表达Red重组酶)的大肠杆菌菌株BW25113中,获得了可用于BmNPV基因打靶的菌株BW25113-Bac。设计一对长63bp的引物(5′端为orf60基因的左右同源臂,长45bp;3′端长18bp,为氯霉素抗性基因(cat)的首尾序列),以pKD3质粒(含cat)为模板,PCR扩增携带orf60左右同源臂的cat,即打靶线性化片段。将该线性化片段电转入BW25113-Bac菌株,在Red重组酶的作用下,线性化片段与BmNPVbacmid中的orf60基因发生同源重组。设计3对特异引物,用PCR方法证明cat成功地替换了BmNPVorf60基因。重组bacmid DNA转染BmN细胞后,Western blot分析未检测到orf60基因的表达。     

ste7与ste15双基因敲除对依博素生物合成的影响

摘要：【目的】研究ste7和ste15基因双敲除对依博素生物合成的影响。【方法】通过基因同源重组双交换,对ste15基因缺失突变株Streptomyces sp. 139 (ste15 -)再进行ste7基因的敲除,经Southern杂交验证,获得了ste7和ste15双基因缺失变株Streptomyces sp. 139 (ste7 - ste15 -)。对该突变株进行了基因互补。气相色谱分析ste7和ste15双基因缺失突变株及互补株产生的胞外多糖单糖组分,排阻色谱测定衍生物的重均分子量,ELISA法     

Pseudomonas plecoglossicida NyZ12基因无痕敲除方法的建立

旨在建立一种适合环己胺降解菌NyZ12基因无痕敲除的可靠方法。通过overlapping PCR技术将目的基因上下游同源臂融合并克隆到自杀载体pEX18km上,将重组质粒转化到大肠杆菌S17pir中,再通过接合转移到假单胞菌NyZ12菌株内,经pEX18km质粒上sacB基因的反向筛选得到突变株并通过PCR方法和测序鉴定。结果显示,成功构建了假单胞菌NyZ12菌株orf4637的基因突变株(NyZ12Δ4637)。通过自杀载体同源重组可以成功获得敲除的无痕突变株,且突变株基因组上没有任何抗性筛选标记残留,为环己胺降解菌NyZ12基因功能研究提供了可靠的基因敲除技术。     

金色链霉菌J13基因敲除体系的构建

目的:建立金色链霉菌基因敲除体系,敲除金色链霉菌J13中的ctcF基因,研究工程菌的代谢变化.方法:采用基因置换和框内缺失技术,对ctcF基因进行敲除.结果:利用接合转移的方法,将质粒pFD109导入到金色链霉菌J13中,经抗性筛选及PCR验证获得ctcF基因置换菌株金色链霉菌A1 - 20;将质粒pFD111经接合转移导入到A1 -20中,获得ctcF基因框内缺失菌株金色链霉菌K2-46;以上工程菌的发酵组分经HPLC分析,发现金霉素发酵单位显著降低.结论:获得的接合子发生双交换的概率可达18％以上,建立及验证了金色链霉菌基因敲除体系的实用性和可操作性,并初步推测ctcF为金霉素生物合成中的调控基因.     

一种以PCR产物直接构建同源重组杆状病毒的方法

发展了一种在不构建载体的前提下, 以PCR产物直接构建同源重组杆状病毒的方法. 这种方法建立在λ噬菌体Red重组系统能介导36 bp以上的同源片段产生同源重组的基础之上. 以棉铃虫单粒包埋型核多角体病毒(HaSNPV)为例, 详细地介绍了以氯霉素抗性基因(CmR)置换HaSNPV基因组中orf135的快速重组过程. 人工合成一对长60 bp左右的引物, 其中40 bp与HaSNPV orf135的头部和尾部序列同源, 另20 bp分别为氯霉素抗性基因的尾部和头部序列. 以含有CmR的质粒pKD3为模板, 利用这对引物PCR合成两侧各有40 bp orf135同源臂的CmR基因, 将此线性片段转化含有HaSNPV人工染色体(Bacmid)且能表达λ噬菌体Red重组酶的菌株中, 获得了缺失orf135并对氯霉素具有抗性的重组转化子. 由于整个过程无需构建载体, 重组过程在大肠杆菌中完成, 使得构建同源重组杆状病毒的过程大大缩短. 这种方法将广泛适用于其他具有较大基因组的病毒的基因置换和基因缺失.     

利用Red系统快速敲除家蚕核型多角体病毒orf60基因

用Red重组系统和最近构建的家蚕核型多角体病毒（BmNPV）bacmid在大肠杆菌BW25113中快速地敲除BmNPV orf60基因。从大肠杆菌BmDH10Bac中提取BmNPV bacmid,将其电转化到含有质粒pKD46（能表达Red重组酶）的大肠杆菌菌株BW25113中,获得了可用于BmNPV基因打靶的菌株BW25113-Bac。设计一对长63bp的引物（5′端为orf60基因的左右同源臂,长45bp;3′端长18bp,为氯霉素抗性基因（cat）的首尾序列）,以pKD3质粒（含cat）为模板,PCR扩增携带orf60左右同源臂的cat,即打靶线性化片段。将该线性化片段电转入BW25113-Bac菌株,在Red重组酶的作用下,线性化片段与BmNPV bacmid中的orf60基因发生同源重组。设计3对特异引物,用PCR方法证明cat成功地替换了BmNPV orf60基因。重组bacmid DNA转染BmN细胞后,Western blot分析未检测到orf60基因的表达。     

利用Red系统快速敲除家蚕核型多角体病毒orf60基因

用Red重组系统和最近构建的家蚕核型多角体病毒（BmNPV）bacmid在大肠杆菌BW25113中快速地敲除BmNPV orf60基因。从大肠杆菌BmDH10Bac中提取BmNPV bacmid,将其电转化到含有质粒pKD46（能表达Red重组酶）的大肠杆菌菌株BW25113中,获得了可用于BmNPV基因打靶的菌株BW25113-Bac。设计一对长63bp的引物（5′端为orf60基因的左右同源臂,长45bp;3′端长18bp,为氯霉素抗性基因（cat）的首尾序列）,以pKD3质粒（含cat）为模板,PCR扩增携带orf60左右同源臂的cat,即打靶线性化片段。将该线性化片段电转入BW25113-Bac菌株,在Red重组酶的作用下,线性化片段与BmNPV bacmid中的orf60基因发生同源重组。设计3对特异引物,用PCR方法证明cat成功地替换了BmNPV orf60基因。重组bacmid DNA转染BmN细胞后,Western blot分析未检测到orf60基因的表达。     

Functional identification of the gene encoding the enzyme involved in mannosylation in ramoplanin biosynthesis in Actinoplanes sp.

Ramoplanin is a lipopeptide antibiotic active against multi-drug-resistant, Gram-positive pathogens. Structurally, it contains a di-mannose moiety attached to the peptide core at Hpg¹¹. The biosynthetic gene cluster of ramoplanin has already been reported and the assembly of the depsipeptide has been elucidated but the mechanism of transferring sugar moiety to the peptide core remains unclear. Sequence analysis of the biosynthetic gene cluster indicated ramo-orf29 was a mannosyltransferase candidate. To investigate the involvement of ramo-orf29 in ramoplanin biosynthesis, gene inactivation and complementation have been conducted in Actinoplanes sp. ATCC 33076 by homologous recombination. Metabolite analysis revealed that the ramo-orf29 inactivated mutant produced no ramoplanin but the ramoplanin aglycone. Thus, ramo-orf29 codes for the mannosyltransferase in the ramoplanin biosynthesis pathway. This lays the foundation for further exploitation of the ramoplanin mannosyltransferase and aglycone in combinatorial biosynthesis.     

The mechanism of action of ramoplanin and enduracidin

The lipoglycodepsipeptide antibiotic ramoplanin is proposed to inhibit bacterial cell wall biosynthesis by binding to intermediates along the pathway to mature peptidoglycan, which interferes with further enzymatic processing. Two sequential enzymatic steps can be blocked by ramoplanin, but there is no definitive information about whether one step is inhibited preferentially. Here we use inhibition kinetics and binding assays to assess whether ramoplanin and the related compound enduracidin have an intrinsic preference for one step over the other. Both ramoplanin and enduracidin preferentially inhibit the transglycosylation step of peptidoglycan biosynthesis compared with the MurG step. The basis for stronger inhibition is a greater affinity for the transglycosylase substrate Lipid II over the MurG substrate Lipid I. These results provide compelling evidence that ramoplanin's and enduracidin's primary cellular target is the transglycosylation step of peptidoglycan biosynthesis.     

A new bacterial mannosidase for the selective modification of ramoplanin and its derivatives

Ramoplanin is a lipoglycodepsipeptide produced by Actinoplanes sp. ATCC 33076 and active on bacterial cell wall biosynthesis by binding to Lipid II. A screening of an actinomycetes collection was performed to select enzymatic activities able to introduce specific modifications in the ramoplanin molecule. An extracellular mannosidase from Streptomyces GE 91081 was found to selectively remove one mannose unit from ramoplanin and tetrahydroramoplanin to give the corresponding mannosyl aglycones. These molecules show an improved microbiological activity versus some resistant staphylococci and streptococci, and are useful intermediates in the synthesis of novel ramoplanin-like antibiotics. The biotransformation of ramoplanin has been optimised to improve molar conversion and the transformation reaction rate.     

A new bacterial mannosidase for the selective modification of ramoplanin and its derivatives

Ramoplanin is a lipoglycodepsipeptide produced by Actinoplanes sp. ATCC 33076 and active on bacterial cell wall biosynthesis by binding to Lipid II. A screening of an actinomycetes collection was performed to select enzymatic activities able to introduce specific modifications in the ramoplanin molecule. An extracellular mannosidase from Streptomyces GE 91081 was found to selectively remove one mannose unit from ramoplanin and tetrahydroramoplanin to give the corresponding mannosyl aglycones. These molecules show an improved microbiological activity versus some resistant staphylococci and streptococci, and are useful intermediates in the synthesis of novel ramoplanin-like antibiotics. The biotransformation of ramoplanin has been optimised to improve molar conversion and the transformation reaction rate.     

Chemistry and biology of the ramoplanin family of peptide antibiotics

The peptide antibiotic ramoplanin factor A2 is a promising clinical candidate for treatment of Gram-positive bacterial infections that are resistant to antibiotics such as glycopeptides, macrolides, and penicillins. Since its discovery in 1984, no clinical or laboratory-generated resistance to this antibiotic has been reported. The mechanism of action of ramoplanin involves sequestration of peptidoglycan biosynthesis Lipid intermediates, thus physically occluding these substrates from proper utilization by the late-stage peptidoglycan biosynthesis enzymes MurG and the transglycosylases (TGases). Ramoplanin is structurally related to two cell wall active lipodepsipeptide antibiotics, janiemycin, and enduracidin, and is functionally related to members of the lantibiotic class of antimicrobial peptides (mersacidin, actagardine, nisin, and epidermin) and glycopeptide antibiotics (vancomycin and teicoplanin). Peptidomimetic chemotherapeutics derived from the ramoplanin sequence may find future use as antibiotics against vancomycin-resistant Enterococcus faecium (VRE), methicillin-resistant Staphylococcus aureus (MRSA), and related pathogens. Here we review the chemistry and biology of the ramoplanins including its discovery, structure elucidation, biosynthesis, antimicrobial activity, mechanism of action, and total synthesis.     

Studies on the biosynthesis of the lipodepsipeptide antibiotic Ramoplanin A2

Ramoplanin, a non-ribosomally synthesized peptide antibiotic, is highly effective against several drug-resistant Gram-positive bacteria, including vancomycin-resistant Enterococcus faecium (VRE) and methicillin-resistant Staphylococcus aureus (MRSA), two important opportunistic human pathogens. Recently, the biosynthetic cluster from the ramoplanin producer Actinoplanes ATCC 33076 was sequenced, revealing an unusual architecture of fatty acid and non-ribosomal peptide synthetase biosynthetic genes (NRPSs). The first steps towards understanding how these biosynthetic enzymes cooperatively interact to produce the depsipeptide product are expression and isolation of each enzyme to probe its specificity and function. Here we describe the successful production of soluble enzymes from within the ramoplanin locus and the confirmation of their specific role in biosynthesis. These methods may be broadly applicable to the production of biosynthetic enzymes from other natural product biosynthetic gene clusters, especially those that have been refractory to production in heterologous hosts despite standard expression optimization methods.     

Chemoenzymatic deacylation of ramoplanin

The chemoenzymatic deacylation of ramoplanin A2 is described for the first time: ramoplanin A2 was Boc-protected and hydrogenated to Boc-protected tetrahydroramoplanin, which was subsequently deacylated using an acylase from Actinoplanes utahensis NRRL 12052. The chemoenzymatic process proceeded with 80% overall yield, which favourably compares with the previously described chemical deacylation.     

Production of ramoplanin analogues by genetic engineering of Actinoplanes sp.

Ramoplanins are lipopeptides effective against a wide range of Gram-positive pathogens. Ramoplanin A2 is in Phase III clinical trials. The structure–activity relationship of the unique 2Z,4E-fatty acid side-chain of ramoplanins indicates a significant contribution to the antimicrobial activities but ramoplanin derivatives with longer 2Z,4E-fatty acid side-chains are not easy to obtain by semi-synthetic approaches. To construct a strain that produces such analogues, an acyl-CoA ligase gene in a ramoplanin-producing Actinoplanes was inactivated and a heterologous gene from an enduracidin producer (Streptomyces fungicidicus) was introduced into the mutant. The resulting strain produced three ramoplanin analogues with longer alkyl chains, in which X1 was purified. The MIC value of X1 was ~0.12 μg/ml against Entrococcus sp. and was also active against vancomycin-resistant Staphylococcus aureus (MIC = 2 μg/ml).     

棉花赤霉素氧化酶同源基因GhGA20ox1在烟草中的功能表达

为研究棉花GA20-氧化酶同源基因GhGA20ox1的功能,将该基因转入本明烟（N．benthamiana）中进行超量表达。RT-PCR分析表明GhGA20ox1基因在转基因植株中得到了不同水平的表达。GhGA20ox1基因的超量表达促进了本明烟中的GA4＋7合成,并导致赤霉素过量的表型出现。转基因本明烟的表型变化程度与GhGA20ox1基因的表达水平和GA4＋7的含量一致。这些结果表明,GhGA20ox1基因编码一个有功能的GA20-氧化酶,能够在转基因烟草中促进活性GA（GA4＋7）的合成,可以用作目的基因来提高棉花纤维和其他植物的内源GA水平。